REG - CelLBxHealth PLC - Research Collaboration with The Royal Marsden

CellbxhealthAnnouncement

20/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST9962Aa&default-theme=true

RNS Number : 9962A  CelLBxHealth PLC  20 April 2026

 

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

 

Research Collaboration with The Royal Marsden NHS Foundation Trust

on novel CTC clinical study in advanced lung cancer

 

·    Clinical study in 200 patients whose circulating tumor DNA (ctDNA)
testing is uninformative

·    CTC-DNA profiling is expected to deliver additional information for
treatment decisions

 

Guildford, UK and Plymouth Meeting, U.S. - 20 April 2026 - CelLBxHealth plc
(AIM:CLBX), a CTC intelligence company specialising in innovative circulating
tumor cell (CTC) solutions for use in research, drug development and clinical
oncology announces a research collaboration with The Royal Marsden NHS
Foundation Trust ("The Royal Marsden"), one of the world's leading cancer
centres.

 

CelLBxHealth and The Royal Marsden will jointly undertake a translational
clinical study in 200 patients with advanced non-small cell lung cancer
(NSCLC). The prospective, single timepoint study will be embedded within an
existing study in which patients are undergoing molecular testing of ctDNA
from blood.

 

In the 10-15% of patients whose ctDNA testing is "uninformative," (meaning it
does not identify actionable genomic mutations), CTC-DNA will be analysed to
uncover actionable mutations that may guide targeted treatment decisions in
this underserved cohort. This approach is supported by studies which have
shown that DNA from CTCs can provide additional actionable mutations(1,2).

 

Secondary objectives include assessing CTC consistency with tumor tissue
profiling and evaluating whether the combined approach increases overall
detection of clinically relevant genomic mutations.

 

The project will be jointly led by Dr Lavanya Sivapalan, Head of R&D at
CelLBxHealth, and Professor Michael Hubank, Scientific Director of the
Clinical Genomics Service at The Royal Marsden. Results of the study are
anticipated by year end and all anonymised data generated during the study
will be shared between both parties to support joint analysis and
translational insights.

 

Peter Collins, Chief Executive Officer of CelLBxHealth, commented: "This
collaboration with The Royal Marsden represents a great opportunity to deliver
precision oncology for a significant number of NSCLC patients for whom
standard of care tissue biopsy and ctDNA analysis is unable to identify
genetic alterations that confer eligibility for a wide range of effective
targeted therapies. By integrating a reflex to CTC-DNA analysis, we aim to
identify those clinically actionable alterations and expand treatment options
for this patient group. We are delighted to partner with a globally recognised
institution to evaluate the potential of this combined approach in a
real-world clinical setting."

 

For further information:

 

 CelLBxHealth plc                                investor@cellbxhealth.com

 Peter Collins, Chief Executive Officer          via Walbrook PR

 Jan Groen, Executive Chairman

 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Investor and Media Relations)      Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

 Paul McManus / Alice Woodings                   Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About The Royal Marsden NHS Foundation Trust

This year marks 175 years of The Royal Marsden. Since 1851, it has led the way
in cancer research, education and treatment, building a legacy of
innovation, compassion and putting patients first. This work has been made
possible by the clinicians, nurses, researchers and support staff, alongside
remarkable donors whose belief in the development of better treatments has
driven this innovation throughout the last 175 years. The inspirational
supporters of The Royal Marsden Cancer Charity remain at the heart of the
hospital's breakthroughs, helping to save the lives of cancer patients around
the world.

 

The Royal Marsden opened in 1851 as the world's first hospital dedicated to
cancer diagnosis, treatment, research and education. Today it operates as
a specialist cancer centre and is ranked in the top 10 specialised hospitals
in the world.

 

The Trust was delighted to welcome Her Royal Highness The Princess of Wales
as Joint Patron with His Royal Highness The Prince of Wales, in January
2025.

 

Together with its principal academic partner, The Institute of Cancer
Research, London, The Royal Marsden is designated as the UK's only National
Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC)
dedicated solely to cancer.

 

The Royal Marsden and the ICR are recognised as one of the top four
comprehensive cancer centres in the world for the impact of their research,
influencing cancer treatment and care for cancer patients globally.

 

As a centre of excellence, we pioneer the very latest in cancer treatments and
technologies, as well as leading the way in innovative cancer diagnosis and
education.

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative
circulating tumor cell (CTC) solutions for use in research, drug development
and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs
from blood and can be integrated with existing laboratory instruments for
comprehensive downstream analysis - including whole-cell imaging, proteomic
profiling and full genomic workflows.

 

Commercial focus span three revenue streams - Product Sales of the Parsortix
platform and consumables through CRO and clinical lab partnerships, Laboratory
Services including clinical trial support and assay development delivered from
a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through
a combination of strategic partnerships and in-house development.

 

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

References

 

1.  Markou, A. N. et al. Preoperative Mutational Analysis of Circulating
Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for
Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung
Cancer. Cancers 15, 1877 (2023).

2.  Wishart, G., Templeman, A., Hendry, F., Miller, K. & Pailhes-Jimenez,
A.-S. Molecular Profiling of Circulating Tumour Cells and Circulating Tumour
DNA: Complementary Insights from a Single Blood Sample Utilising the
Parsortix® System. Curr. Issues Mol. Biol. 46, 773-787 (2024).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBUVRNNUSAAR



            Copyright 2019 Regulatory News Service, all rights reserved